expanding the right to try act to include certain qualifying severe illness and permitting certain regenerative stem cell therapies under the act.
Interim Study Report: Recommended for Future Legislation 10/05/2026 (Vote 7-6; )
Email me when HB 1292 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HB 1292. By continuing you agree to the Terms and Privacy Policy.
Summary
The bill would let patients with chronic, debilitating illnesses—not just terminal ones—access unapproved drugs, biologics, devices, and certain stem‑cell treatments. It sets rules for physicians, facilities, and manufacturers, including consent forms, accreditation requirements, and advertising notices. The measure also protects doctors and clinics from license actions and gives patients the right to sue for violations.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HB 1292
3 free questions a day, no accountHistory
- Refer for Interim Study: MA VV 03/05/2026 HJ 6
- Committee Report: Refer for Interim Study 02/13/2026 (Vote 17-1; CC) HC 9 P. 18
- Public Hearing: 02/11/2026 01:00 pm GP 230
- Executive Session: 02/13/2026 10:00 am GP 158
- Introduced 01/07/2026 and referred to Judiciary HJ 1 P. 14
Sponsors
- Erica Layon (R) · sponsor
- Cyril Nicholas Aures
- Dan McGuire
- Daniel Popovici-Muller
- Erica J Layon
- Keith R. Murphy
- Mary Murphy
- Matt R Sabourin dit Choinière
- Sayra Lynn DeVito
- Victoria Sullivan
- Yury Polozov
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HB 1292 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HB 1292 freeOr ask your AI assistant about HB 1292 directly:
Add to Claude, ChatGPT or Cursor